Prednefrin

Prednefrin is an ophthalmic corticosteroid brand marketed by Laboratorios Sophia, primarily used for the management of ocular inflammation and pain. The specific formulation frequently cited in clinical trials, Prednefrin SF, contains 1% prednisolone acetate and is indicated for treating steroid-responsive inflammatory conditions of the eye, including postoperative inflammation and pain following cataract surgery (phacoemulsification). As a potent glucocorticoid, it functions by binding to cytoplasmic glucocorticoid receptors, which subsequently inhibits the expression of pro-inflammatory genes and reduces the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. This action effectively suppresses the inflammatory cascade, reducing cellular infiltration and flare in the anterior chamber. In the context of Laboratorios Sophia's development pipeline, Prednefrin SF serves as the gold-standard active comparator for evaluating the efficacy and safety of newer ophthalmic steroids and generic formulations like PRO-145 (difluprednate).

Brand names

PrednefrinPrednefrin SF

Other names

prednisolone acetateprednisolona acetato